SCHEMBL15560209

SCHEMBL15560209

Clc1ccccc1/C=C/COCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.47
TSHR P16473 1/20 0.45
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
GRIK1 P39086 1/20 0.40
GRIK2 Q13002 1/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
IDO1 P14902 1/20 0.38
NFE2L2 Q16236 3/20 0.38
RELA Q04206 1/20 0.38
TK1 P04183 1/20 0.37
FGFR1 P11362 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17093332 1.00 ALOX5 (0.47) ALOX5TSHRGRIN1GRIN2BNPC1
SCHEMBL30443957 1.00 ALOX5 (0.47) ALOX5TSHRGRIN1GRIN2BNPC1
SCHEMBL9252336 0.86 ALDH1A1 (0.45) GRIN1GRIN2BNPC1RAB9AHPGD
SCHEMBL12301106 0.80 ALOX5 (0.50) ALOX5TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL1524411 0.78 TSHR (0.67) ALOX5TSHRIDO1TK1AGXT
SCHEMBL1524101 0.78 TSHR (0.67) ALOX5TSHRIDO1TK1AGXT
SCHEMBL1524098 0.78 TSHR (0.67) ALOX5TSHRIDO1TK1AGXT
SCHEMBL1157829 0.77 ALOX5 (0.60) ALOX5TSHRLMNAIDO1
SCHEMBL1157826 0.77 ALOX5 (0.60) ALOX5TSHRLMNAIDO1
SCHEMBL30444298 0.77 NFE2L2 (0.45) GRIK1GRIK2NFE2L2RELAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-02-13 US disclosed
EP-4211125-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-19 EP disclosed
CN-116234798-A Sulfamate derivative compounds for the treatment or alleviation of psychotic disorders 生物药品解决方案有限公司 2023-06-06 CN disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
WO-2022054987-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-03-17 WO disclosed
CN-106507667-B Sulfamate derivatives for the prevention or treatment of epilepsy 比皮艾思药物研发有限公司 2020-01-24 CN disclosed
EP-3443959-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2019-02-20 EP disclosed
EP-3079685-B1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO PHARM SOLUTIONS CO LTD (KR) 2018-11-28 EP disclosed
EP-3079686-B1 SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY BIO PHARM SOLUTIONS CO LTD (KR) 2018-10-24 EP disclosed
EP-3079685-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2016-10-19 EP disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
WO-2015088273-A9 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-08-06 WO disclosed
WO-2015088273-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-06-18 WO disclosed
WO-2015088271-A1 SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-06-18 WO disclosed
EP-2861571-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME Bio-Pharm Solutions Co., Ltd. (KR) 2015-04-22 EP disclosed
WO-2013187727-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER SLC6A4, SLC6A3, SLC6A2 ALOX5 1341/4885TSHR 2322/4885GRIN1 49/4885
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME MYLK, MUSK, MYLK2 ALOX5 369/4885TSHR 2872/4885GRIN1 1280/4885
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder SLC6A4, SLC6A3, SLC6A2 ALOX5 1341/4885TSHR 2322/4885GRIN1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.